Abstract: The present invention relates to a formulation containing Mesalazine in a stable form, obtained by coating the starting core with a first membrane in non-aqueous solution; said core containing Mesalazine at a high concentration, greater than 90%, obtained by producing starting cores with Active Substance content greater than 97%. The formulation according to the present invention containing Mesalazine with specific release in the colon; in particular the capsule formulation containing 500 mg of Mesalazine with specific release in the colon.

Abstract: Sustained-release Gliclazide tablets devoid of calcium phosphate dibasic, and containing only soluble excipients. The mixing of two high viscosity HPMC with a low viscosity one allows to obtain releases similar to those of the reference products on the market, and it shows also a certain pH dependence.

Abstract: Formulations for the preparation of immediate-release tablets for oral use containing low-dose mifepristone for the treatment of endometriosis, tablets thus obtained and their preparation process, are described.

Abstract: Formulations for the preparation of immediate-release tablets for oral administration containing low-dose mifepristone, the tablets thus obtained and their preparation process, are described.

Abstract: The present invention relates to pharmaceutical formulations comprising a layer of compressed granules to facilitate the administration of oral PPI.

Abstract: A pharmaceutical composition for the oral administration of omega polyenoic fatty acids combined with one or more active principles incompatible therewith, is described; also described is a process for preparing said pharmaceutical composition.

Abstract: Herein is described a controlled release pharmaceutical composition of venlafaxine hydrochloride, an effective antidepressant, comprising an inert core; on which the active principle is uniformly layered, that in turn is coated with a layer comprising a hardening agent and a lipophilic agent; the process for the preparation of said pharmaceutical composition is also described.

Abstract: Modified release formulation of lithium carbonate in microgranules or similar comprising, for around 300 Kg of Lithium Carbonate, at least: Overall Povidone in quantity between 8.0 Kg and 40.0 Kg; Ethylcellulose in quantity between Kg 0.9 and Kg 3.6.

Abstract: Oral solid pharmaceutical compositions with pH-dependent multiphasic release, containing, as active ingredient, a molecule useful in the inflammatory bowel disease therapy, are described, being such compositions suitable to the release of the active ingredient in the intestinal tract.

Abstract: This invention refers to: multiparticulate formulations of Lithium salts for oral administration constituted by either modified release granules or mixtures of modified and conventional release granules, suitable for once-a-day administration also at high strengths of Lithium salts, and to the preparation process of said formulations.

Abstract: This invention refers to: multiparticulate formulations of Lithium salts for oral administration constituted by either modified release granules or mixtures of modified and conventional release granules, suitable for once-a-day administration also at high strengths of Lithium salts, and to the preparation process of said formulations.

Abstract: Use of at least one 4 amino-quinolinic derivative to obtain a drug for the anti-retroviral therapy, especially in the therapy of the HIV disease-infection caused by retroviral strains, which are sensitive and/or resistant to known therapies.

Abstract: Formulations for the oral administration of NADH in multiparticulate enteric coated form and/or dosed either into gelatine capsules or sachets or dispensers

Abstract: Pharmaceutical composition in modified release tablet form containing Bupropion HCl as active substance and including, at the same time, hydrophilic components and hydrophobic ingredients mixed with an excipient substance.

Abstract: This invention refers to:

Abstract: Oral solid pharmaceutical compositions with pH-dependent multiphasic release, containing, as active ingredient, a molecule useful in the inflammatory bowel disease therapy, are described; being such compositions suitable to the release of the active ingredient in the intestinal tract.

Abstract: Controlled release pharmaceutical compositions for the oral administration of nifedipine are disclosed which comprise an amorphous coprecipitate of nifedipine and polyvinylpyrrolidone with suitable excipients. The release rate may be varied from 8 to 24 hours by varying the amounts of the cellulose derivative, the carboxypolymethylene and the lactose.

Abstract: A pharmaceutical oral controlled release composition comprising a multiplicity of microgranules or pellets, each of said pellets consisting of a core of active ingredient and binder and of a membrane applied upon said core, is described, wherein the active ingredient is a bile acid and the pellets have a particle-size of from 400 to 2000 microns.

Abstract: Controlled release pellets consisting of an inert material, a medicament layer and a coating membrane of a mixture or stearic acid and ethyl cellulose or of parrafin and methacrylic acid copolymer.

Abstract: The present invention relates to the pharmaceutical field and particularly to the manufacturing of a pharmaceutical product named etofibrate in the form of sustained release microgranules, wherein each microgranule consists entirely of an etofibrate composition and polyethylene glycol 4000, said microgranules being placed in capsules that, size of known capsules being equal, display an higher concentration of the active ingredient, the process for preparing the above mcrogranules comprising mainly the manufacturing of a compound consisting of etofibrate and solvent, wherein said compound is obtained in rotatory pan, then submitting this compound to a first sieving, placing it again in rotatory pan, drying the product thus obtained and sieving it once more, separating the microgranules which are replaced in the rotatory pan and then coated in rotatory pan with further etofibrate added with a suitable amount of polyethylene glycol 4000 to give, after a last sieving, the desired microgranules whose size correspo